Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 3Sarcoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Liver Neoplasms 1Leukemia, Plasma Cell 1Desmoid Tumors 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 3atezolizumab 2Radiotherapy 2Bevacizumab 2tremelimumab 1temsirolimus 1lonafarnib 1liposomal doxorubicin 1infigratinib 1gadolinium ethoxybenzyl DTPA 1fludarabine 1durvalumab 1cabozantinib 1bavituximab 1aldesleukin 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Resveratrol 1Radiosurgery 1Radionuclide Generators 1Radiofrequency Ablation 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1NSC 366140 1Mass Spectrometry 1Immunotherapy 1Immunohistochemistry 1Genetic Testing 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × liposomal doxorubicin × Clear all
NCT01281943 2013-07-04

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡